Chiara Pozzessere1,2, Maria Bassanelli3, Anna Ceribelli3, Sazan Rasul4, Shuren Li4, John O Prior5, Francesco Cicone5. 1. Department of Radiology, AUSL Toscana Centro San Giuseppe Hospital, Viale Boccaccio 20, 50053, Empoli, Italy. chiara.pozzessere@gmail.com. 2. Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. chiara.pozzessere@gmail.com. 3. Division of Medical Oncology, San Camillo De Lellis Hospital, Rieti, Italy. 4. Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria. 5. Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Abstract
PURPOSE OF REVIEW: To critically review the potential clinical applications of prostate-specific membrane antigen (PSMA) radioactive ligands in renal cell carcinoma (RCC). RECENT FINDINGS: Radioactive probes targeting PSMA hold promise in several malignancies in addition to prostate cancer, owing to the expression of PSMA by tumor neovasculature. The majority of clear cell RCCs (ccRCC), the most malignant RCC subtype, express PSMA on tumor-associated neovasculature. The endothelium of less aggressive RCC subtypes is PSMA positive in a lower, but still significant percentage of cases. PSMA might therefore represent an interesting theragnostic target in RCC. The preliminary data available suggest a potential role for PSMA-targeting radiopharmaceuticals in complementing conventional imaging for staging ccRCC patients at risk of nodal involvement and oligometastatic disease. Additional applications of PSMA imaging may be the selection and the response assessment of patients receiving anti-angiogenic treatments. The effectiveness of PSMA-targeting radionuclide therapy should also be investigated.
PURPOSE OF REVIEW: To critically review the potential clinical applications of prostate-specific membrane antigen (PSMA) radioactive ligands in renal cell carcinoma (RCC). RECENT FINDINGS: Radioactive probes targeting PSMA hold promise in several malignancies in addition to prostate cancer, owing to the expression of PSMA by tumor neovasculature. The majority of clear cell RCCs (ccRCC), the most malignant RCC subtype, express PSMA on tumor-associated neovasculature. The endothelium of less aggressive RCC subtypes is PSMA positive in a lower, but still significant percentage of cases. PSMA might therefore represent an interesting theragnostic target in RCC. The preliminary data available suggest a potential role for PSMA-targeting radiopharmaceuticals in complementing conventional imaging for staging ccRCC patients at risk of nodal involvement and oligometastatic disease. Additional applications of PSMA imaging may be the selection and the response assessment of patients receiving anti-angiogenic treatments. The effectiveness of PSMA-targeting radionuclide therapy should also be investigated.
Authors: F Ruatta; L Derosa; B Escudier; E Colomba; A Guida; G Baciarello; Y Loriot; K Fizazi; L Albiges Journal: Eur J Cancer Date: 2018-12-11 Impact factor: 9.162
Authors: Ronnie C Mease; Crystal L Dusich; Catherine A Foss; Hayden T Ravert; Robert F Dannals; Jurgen Seidel; Andrew Prideaux; James J Fox; George Sgouros; Alan P Kozikowski; Martin G Pomper Journal: Clin Cancer Res Date: 2008-05-15 Impact factor: 12.531
Authors: Robert J Motzer; Bernard Escudier; David F McDermott; Saby George; Hans J Hammers; Sandhya Srinivas; Scott S Tykodi; Jeffrey A Sosman; Giuseppe Procopio; Elizabeth R Plimack; Daniel Castellano; Toni K Choueiri; Howard Gurney; Frede Donskov; Petri Bono; John Wagstaff; Thomas C Gauler; Takeshi Ueda; Yoshihiko Tomita; Fabio A Schutz; Christian Kollmannsberger; James Larkin; Alain Ravaud; Jason S Simon; Li-An Xu; Ian M Waxman; Padmanee Sharma Journal: N Engl J Med Date: 2015-09-25 Impact factor: 91.245
Authors: J T Pinto; B P Suffoletto; T M Berzin; C H Qiao; S Lin; W P Tong; F May; B Mukherjee; W D Heston Journal: Clin Cancer Res Date: 1996-09 Impact factor: 12.531
Authors: Stefanie Zschäbitz; Franziska Erlmeier; Christine Stöhr; Edwin Herrmann; Iris Polifka; Abbas Agaimy; Lutz Trojan; Philipp Ströbel; Frank Becker; Christian Wülfing; Peter Barth; Michael Stöckle; Michael Staehler; Christian Stief; Axel Haferkamp; Markus Hohenfellner; Stephan Macher-Göppinger; Bernd Wullich; Joachim Noldus; Walburgis Brenner; Frederik C Roos; Bernhard Walter; Wolfgang Otto; Maximilian Burger; Andres Jan Schrader; Yvonne Mondorf; Arndt Hartmann; Philipp Ivanyi; Sandra Steffens Journal: J Cancer Date: 2022-03-14 Impact factor: 4.207
Authors: Falk Gühne; Philipp Seifert; Bernhard Theis; Matthias Steinert; Martin Freesmeyer; Robert Drescher Journal: Diagnostics (Basel) Date: 2021-06-23